Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Antley-Bixler syndrome is a very rare disorder characterized by craniosynostosis with midface hypoplasia, radiohumeral synostosis, femoral bowing and joint contractures.
Features include very common findings: Brachycephaly, Delayed cranial suture closure, Posteriorly rotated ears, and Anteverted nares and others; and common findings: Choanal atresia, Proptosis, Craniosynostosis, and Abnormal renal morphology. 30 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 5 | Joint stiffness, Femoral bowing, Narrow pelvis bone |
Cytochrome P450 oxidoreductase deficiency (PORD) is an autosomal recessive disorder with a broad phenotypic spectrum including skeletal malformations resembling the Antley-Bixler syndrome (ABS) phenotype and abnormalities in adrenal steroid biosynthesis resulting in congenital adrenal hyperplasia (CAH).
Skeletal abnormalities. PORD should be suspected in individuals with features of ABS. Affected individuals may present with the following congenital craniofacial and skeletal anomalies:
No approved treatments are currently available for Antley-Bixler syndrome. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with PORD, the following evaluations are recommended:
Evaluations by appropriate specialists in endocrinology, clinical genetics, neurosurgery, otolaryngology, and cardiology
Individuals with PORD should be seen by a specialist tertiary pediatric endocrine service throughout childhood to closely monitor their development and adjust steroid supplementation. Because of the presence of developmental delays in many individuals with ABS, periodic formal developmental assessments may be indicated. However, interpretation of these assessments may be complicated by the physical limitations of the disorder. Screening evaluations are likely to underestimate cognitive abilities. Therefore, evaluations should be done in centers with expertise and experience in developmental testing.
No clinical trials have been registered for Antley-Bixler syndrome.
7 publications have been identified in PubMed for Antley-Bixler syndrome. Research spans Basic Science / Preclinical (43%), Review / Meta-Analysis (29%), and Case Report / Case Series (14%).
Zhang C (2026). [PMID: 42039121](https://pubmed.ncbi.nlm.nih.gov/42039121/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Zhang XJ (2026). [PMID: 42125235](https://pubmed.ncbi.nlm.nih.gov/42125235/). *Front Endocrinol (Lausanne)*. [Basic Science / Preclinical]
Leduc F (2025). [PMID: 40673520](https://pubmed.ncbi.nlm.nih.gov/40673520/). *Clinical genetics*. [Review / Meta-Analysis]
Zhang D (2025). [PMID: 40533672](https://pubmed.ncbi.nlm.nih.gov/40533672/). *Reproductive sciences (Thousand Oaks, Calif.)*. [Epidemiology / Natural History]
Chen F (2025). [PMID: 40659633](https://pubmed.ncbi.nlm.nih.gov/40659633/). *Cell death discovery*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:06 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Antley-Bixler syndrome
Head and neck |
2 |
Craniosynostosis, Cleft palate |
Arms and legs | 1 | Camptodactyly of finger |
Kidneys and urinary system | 1 | Abnormal renal morphology |
Eyes | 1 | Strabismus |
The natural history of cytochrome P450 oxidoreductase deficiency (PORD) varies because it encompasses a wide phenotypic spectrum. However, steroid abnormalities, which occur in all individuals with PORD, can be associated with a number of characteristics. The summary of clinical characteristics is based on 26 studies on 140 individuals with molecularly confirmed PORD published to date (June 2017). Cortisol deficiency found in PORD varies, but is present in the majority of individuals. Based on ACTH stimulation tests, reported severe cortisol deficiency (requiring permanent hydrocortisone replacement) in 43% of individuals, and partial cortisol deficiency (requiring glucocorticoid replacement during stress only) in 40%; no replacement was required in 10% of the cohort.
Source: GeneReviews — "Cytochrome P450 Oxidoreductase Deficiency"
Congenital adrenal hyperplasia (CAH) is a heterogeneous group of autosomal recessive conditions that result in impaired synthesis of cortisol, mineralocorticoids, and/or sex steroids. Based on this definition, the term CAH can be used to describe cytochrome P450 oxidoreductase deficiency (PORD). PORD and the following etiologies of CAH may be distinguished by differences in urinary steroid profiles, molecular genetic testing, and/or the presence of skeletal anomalies, as skeletal anomalies are never found in other forms of CAH, but may occur in PORD. POR acts as an electron donor to two major steroidogenic enzymes, CYP21A2 and CYP17A1. Therefore, individuals with POR show biochemical features of both 21-hydroxylase and 17-hydroxylase deficiency.
21-hydroxylase deficiency
Source: GeneReviews — "Cytochrome P450 Oxidoreductase Deficiency"
Assessment for airway problems in individuals with skeletal malformations
Functional adrenal studies (cosyntropin test) to assess glucocorticoid deficiency, regardless of the presence or absence of genital abnormalities
Additional studies that may be indicated:
Cranial CT scan and/or MRI to determine the degree of craniosynostosis, hydrocephaly, choanal stenosis, and orbital depth
Radiographs to identify long-bone fractures and/or bowing, bony synostoses, and/or joint contractures
Echocardiogram if a heart defect is suspected
Abdominal and pelvic ultrasound examination to identify internal sex organs, detect any renal anomalies, and detect and monitor ovarian cysts in adolescent girls.
Treatment of Manifestations
Cortisol deficiency
Regular hydrocortisone replacement therapy is indicated if baseline serum cortisol concentrations are low.
Stress-dose steroids should be provided perioperatively and during times of physiologic stress in individuals in whom cortisol response to ACTH stimulation (cosyntropin test) is below normal .
Genital abnormalities
Source: GeneReviews — "Cytochrome P450 Oxidoreductase Deficiency"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Cytochrome P450 Oxidoreductase Deficiency"
View trials for Antley-Bixler syndrome
Source: GeneReviews — "Cytochrome P450 Oxidoreductase Deficiency"
Phenotype severity distribution: 16 very common features, 4 common features.
Estimated prevalence: Unknown (Unknown prevalence).
Miller WL (2025). [PMID: 39574227](https://pubmed.ncbi.nlm.nih.gov/39574227/). *The Journal of clinical endocrinology and metabolism*. [Basic Science / Preclinical]
AI-curated news mentioning Antley-Bixler syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.